Regulating effect of lncRNA on aerobic glycolysis in tumor cells

doi:10.3760/cma.j.issn.1673-422X.2019.03.008

Abstract

Abstract: Long noncoding RNA (lncRNA) is a kind of RNA with a length greater than 200 nucleotides and lacks proteincoding function. Varieties of lncRNAs have been found to play major roles in the aerobic glycolysis of tumor cells, such as lncRNAp21, H19, prostate specific transcript 1 (PGCEM1) and so on. In tumor cells, lncRNA can directly regulate the ratelimiting enzyme in the glycolytic pathway, also can indirectly regulate the glycolysis by hypoxia inducible factor1α (HIF1α) or protooncogene cmyc. Further study on the mechanism of lncRNA regulating tumor cell glycolysis is expected to open up new ideas for the diagnosis and treatment of tumor diseases.

Key words: Neoplasms, Glycolysis, RNA, long noncoding

Zhong Chenyi, Mao Yundong. Regulating effect of lncRNA on aerobic glycolysis in tumor cells[J]. Journal of International Oncology, 2019, 46(3): 170-173.

References

［1］ SalcianoSilca A, LoboAlves SC, Almeida RC, et al. Besides pathology: long noncoding RNA in cell and tissue homeostasis［J］. Noncoding RNA, 2018, 4(1): pii: E3. DOI: 10.3390/ncrna4010003. ［2］ Kang W, Zheng Q, Lei J, et al. Prognostic value of long noncoding RNAs in patients with gastrointestinal cancer: a systematic review and metaanalysis［J］. Dis Markers, 2018, 2018: 5340894. DOI: 10.1155/2018/5340894. ［3］ Yu L, Chen X, Sun X, et al. The glycolytic switch in tumors: how many players are involved?［J］. J Cancer, 2017, 8(17): 34303440. DOI: 10.7150/jca.21125. ［4］ Hofmann P. Cancer and exercise: Warburg hypothesis, tumour metabolism and highintensity anaerobic exercise［J］. Sports (Basel), 2018, 6(1): pii: E10. DOI: 10.3390/sports6010010. ［5］ Zhao M, Fan J, Liu Y, et al. Oncogenic role of the TP53induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NFκB pathway modulation［J］. Int J Oncol, 2016, 48(2): 756764. DOI: 10.3892/ijo.2015.3297. ［6］ Panisova E, Kery M, Kopacek J, et al. Enhanced metabolism as a common feature of cancer plasticity［J］. Neoplasma, 2016, 63(6): 836845. DOI: 10.4149/neo_2016_602. ［7］ Ye Y, He X, Lu F, et al. A lincRNAp21/miR181 family feedback loop regulates microglial activation during systemic LPS and MPTP induced neuroinflammation［J］. Cell Death Dis, 2018, 9(8): 803. DOI: 10.1038/s4141901808215. ［8］ Tang SS, Zheng BY, Xiong XD. LincRNAp21: implications in human diseases［J］. Int J Mol Sci, 2015, 16(8): 1873218740. DOI: 10.3390/ijms160818732. ［9］ Shen Y, Liu Y, Sun T, et al. LincRNAp21 knockdown enhances radiosensitivity of hypoxic tumor cells by reducing autophagy through HIF1/Akt/mTOR/P70S6K pathway［J］. Exp Cell Res, 2017, 358(2): 188198. DOI: 10.1016/j.yexcr.2017.06.016. ［10］ Peng F, Wang JH, Fan WJ, et al. Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia［J］. Oncogene, 2018, 37(8): 1119. DOI: 10.1038/onc.2017.407. ［11］ Zhang S, Li Z, Zhang L, et al. MEF2activated long noncoding RNA PCGEM1 promotes cell proliferation in hormonerefractory prostate cancer through downregulation of miR148a［J］. Mol Med Rep, 2018, 18(1): 202208. DOI: 10.3892/mmr.2018.8977. ［12］ ArriagaCanon C, De La Rosa aVelázquez IA, GonzálezBarrios R, et al. The use of long noncoding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer［J］. Oncotarget, 2018, 9(29): 2087220890. DOI: 10.18632/oncotarget.25038. ［13］ Aird J, Baird AM, Lim MCJ, et al. Carcinogenesis in prostate cancer: the role of long noncoding RNAs［J］. Noncoding RNA Res, 2018, 3(1): 2938. DOI: 10.1016/j.ncrna.2018.01.001. ［14］ Kim T, Croce CM. Long noncoding RNAs: undeciphered cellular codes encrypting keys of colorectal cancer pathogenesis［J］. Cancer Lett, 2018, 417: 8995. DOI: 10.1016/j.canlet.2017.12.033. ［15］ Szafron LM, Balcerak A, Grzybowska EA, et al. The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients［J］. Oncotarget, 2015, 6(41): 4389743910. DOI: 10.18632/oncotarget.6016. ［16］ Esposti DD, HernandezVargas H, Voegele C, et al. Identification of novel long noncoding RNAs deregulated in hepatocellular carcinoma using RNAsequencing［J］. Oncotarget, 2016, 7(22): 3186231877. DOI: 10.18632/oncotarget.7364. ［17］ Kong Y, Hsieh CH, Alonso LC. ANRIL: a lncRNA at the CDKN2A/B locus with roles in cancer and metabolic disease［J］. Front Endocrinol (Lausanne), 2018, 9: 405. DOI: 10.3389/fendo.2018.00405. ［18］ Zou ZW, Ma C, Medoro L, et al. LncRNA ANRIL is upregulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing sidepopulation stemlike cancer cells［J］. Oncotarget, 2016, 7(38): 6174161754. DOI: 10.18632/oncotarget.11437. ［19］ Lin A, Li C, Xing Z, et al. The LINKA lncRNA activates normoxic HIF1alpha signalling in triplenegative breast cancer［J］. Nat Cell Biol, 2016, 18(2): 213224. DOI: 10.1038/ncb3295. ［20］ Heneberg P. Redox regulation of hexokinases［J］. Antioxid Redox Signal, 2019, 30(3): 415442. DOI: 10.1089/ars.2017.7255. ［21］ Zhang Y, Liu Y, Xu X. Knockdown of LncRNAUCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA125a/hexokinase 2 pathway［J］. J Cell Biochem, 2018, 119(7): 62966308. DOI: 10.1002/jcb.26899. ［22］ Ma J, Fan Y, Feng T, et al. HOTAIR regulates HK2 expression by binding endogenous miR125 and miR143 in oesophageal squamous cell carcinoma progression［J］. Oncotarget, 2017, 8(49): 8641086422. DOI: 10.18632/oncotarget.21195. ［23］ Song J, Wu X, Liu F, et al. Long noncoding RNA PVT1 promotes glycolysis and tumor progression by regulating miR497/HK2 axis in osteosarcoma［J］. Biochem Biophys Res Commun, 2017, 490(2): 217224. DOI: 10.1016/j.bbrc.2017.06.024. ［24］ Xiao ZD, Zhuang L, Gan B. Long noncoding RNAs in cancer metabolism［J］. Bioessays, 2016, 38(10): 991996. DOI: 10.1002/bies.201600110. ［25］ Fan C, Tang Y, Wang J, et al. Role of long noncoding RNAs in glucose metabolism in cancer［J］. Mol Cancer, 2017, 16(1): 130. DOI: 10.1186/s1294301706993. ［26］ Luo F, Liu X, Ling M, et al. The lncRNA MALAT1, acting through HIF1α stabilization, enhances arseniteinduced glycolysis in human hepatic L02 cells［J］. Biochim Biophys Acta, 2016, 1862(9): 16851695. DOI: 10.1016/j.bbadis.2016.06.004. ［27］ Zhang P, Cao L, Fan P, et al. LncRNAMIF, a cmycactivated long noncoding RNA, suppresses glycolysis by promoting FBXW7mediated cmyc degradation［J］. EMBO Rep, 2016, 17(8): 12041220. DOI: 10.15252/embr.201642067. ［28］ Xiao C, Wu C, Hu HZ. LncRNA UCA1 promotes epithelialmesenchymal transition (EMT) of breast cancer cells via enhancing Wnt/betacatenin signaling pathway［J］. Eur Rev Med Pharmacol Sci, 2016, 20(13): 28192924. ［29］ Rrpaimoole R, Lee J, Haemmerle M, et al. Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis［J］. Cell Rep, 2015, 13(11): 23952402. DOI: 10.1016/j.celrep.2015.11.047.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.